Skip to content
Boca Raton City Online – Lifestyle
Author:
Legend Biotech USA Inc.
Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting
September 10, 2026
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
September 1, 2026
Legend Biotech Reports Second Quarter 2026 Results and Recent Highlights
August 11, 2026
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
July 28, 2026
Legend Biotech Announces CEO Transition
July 27, 2026
Legend Biotech Corporation Announces Pricing of Public Offering
June 17, 2026
Legend Biotech Corporation Announces Proposed Public Offering
June 17, 2026
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 15, 2026
Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 14, 2026
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
June 2, 2026
1
2
Next Page
→